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Abstract
Despite the introduction of newly developed drugs such as lenalidomide and bortezomib, patients with multiple myeloma
are still difficult to treat and have a poor prognosis. In order to find novel drugs that are effective for multiple myeloma, we
tested the antitumor activity of 29 phthalimide derivatives against several multiple myeloma cell lines. Among these
derivatives, 2-(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3- dione (TC11) was found to be a potent inhibitor of tumor
cell proliferation and an inducer of apoptosis via activation of caspase-3, 8 and 9. This compound also showed in vivo
activity against multiple myeloma cell line KMS34 tumor xenografts in ICR/SCID mice. By means of mRNA display selection
on a microfluidic chip, the target protein of TC11 was identified as nucleophosmin 1 (NPM). Binding of TC11 and NPM
monomer was confirmed by surface plasmon resonance. Immunofluorescence and NPM knockdown studies in HeLa cells
suggested that TC11 inhibits centrosomal clustering by inhibiting the centrosomal-regulatory function of NPM, thereby
inducing multipolar mitotic cells, which undergo apoptosis. NPM may become a novel target for development of antitumor
drugs active against multiple myeloma.
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Introduction
Multiple myeloma is one of the hematopoietic organ tumors
which is characterized by the monoclonal proliferation of
malignant plasma cells, resulting in appearance of serum or
urinary monoclonal protein [1–3]. Although treatments include
chemotherapy with melphalan, prednisolone or cyclophospha-
mide, as well as hematopoietic stem cell transplantation [4–8],
most patients become refractory to the therapy and this leads to
a fatal outcome. A group of high-risk patients is exclusively
poorly responsive, with short survival. Tumor cells derived from
high-risk patients have deletion of chromosome 17 (del 17), on
which the p53 tumor suppressor gene is located, deletion of
chromosome 13 or chromosomal translocation t(4;14) accom-
panied with constitutive activation of FGFR-3 on chromosome
4 [9–11]. Therefore, development of novel drugs which are
active against multiple myeloma cells with these high-risk
chromosomal or genetic alterations is necessary to improve
the prognosis. Moreover, elucidation of the mechanisms of
growth suppression of multiple myeloma cells is expected to
improve our understanding of the molecular pathogenesis of
multiple myeloma. Hence, our aim in this study was to find a
novel anti-tumor drug for multiple myeloma and to elucidate its
molecular mechanism of action.
Drugs such as thalidomide, lenalidomide, and bortezomib
show anti-tumor effect on multiple myeloma and have received
much attention in recent years [12–14]; however, even these
potent drugs are of limited value in high-risk cases [15]. Here,
we tested the growth-inhibitory effect of 29 phthalimide
derivatives, which are similar in structure to thalidomide,
against several multiple myeloma cell lines including those with
del 17 or t(4;14). We found that one of these derivatives, 2-(2,6-
diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione (TC11),
showed potent inhibition of tumor cell proliferation both in
vitro and in vivo, and induced apoptosis. Furthermore, we utilized
mRNA display [16] to identify nucleophosmin 1 (NPM/B23), a
nucleolar phosphoprotein [17,18], as a target of TC11 for
inducing apoptosis of tumor cells. Inhibiting the function of
NPM led to induction of multipolar mitoses by blocking
centrosomal clustering, and this leads to cell death. Our results
thus indicate that NPM could be a novel target for development
of anticancer drugs to overcome the poor prognosis of high-risk
multiple myeloma patients.
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Screening of Synthetic Phthalimide Derivatives to
Identify Compounds Inhibiting Multiple Myeloma Cell
Proliferation
Initially, we tested 29 phthalimide derivatives, TC1-29, each of
which has various functional groups (Figure S1), for activity to
inhibit proliferation of multiple myeloma KMS34 cells with t(4;14)
and del 17. In the first screening, we performed cell proliferation
assay to examine inhibitory activity. KMS34 cells were incubated
with 50 mM of each compound for 0, 24, 48 or 72 h and the cell
viability was determined with WST-1 assay. Nine compounds,
TC8, TC9, TC10, TC11, TC12, TC13, TC14, TC15, and TC16,
showed growth-inhibitory activity, while the others were inactive
(Figure S2A). Therefore, we further examined the active
compounds.
To identify the most potent compound, we investigated the
ability of the hit compounds from the first screening to inhibit
proliferation or to induce apoptosis of several multiple myeloma
cell lines. In the second screening, KMM1, KMS11, KMS27,
KMS34 and RPMI8226 cells were incubated with 0–50 mM TC8,
TC9, TC10, TC11, TC12, TC13, TC14, TC15, and TC16. One
arm of chromosome 17 is deleted in KMM1, KMS11 and KMS34
cells, and KMS11 and KMS34 also show t(4;14) (our unpublished
data). In this screening, TC11 and TC13 showed potent activity
against all cell lines tested, with IC50 values of 4–8 mM and 4–
11 mM, respectively (Table 1). Furthermore, we tested the
apoptosis-inducing activity of TC11 and TC13. The results
indicated that TC11 required a lower concentration or a shorter
treatment time to induce apoptosis of several multiple myeloma
cell lines (Figure S2B). Thus, we identified TC11 as the most
potent compound, capable of inhibiting multiple myeloma cell
lines with high-risk chromosomal changes, t(4;14) and del 17.
To optimize the potency of TC11, we further synthesized TC11
derivatives TC30-42 (Figure 1) and tested them. KMS34 cells were
incubated with 0–50 mM TC11 derivatives for 72 h and the cell
viability was assayed. First of all, to examine the importance of the
position of the amino group in the phthalimide moiety, we
synthesized 7 derivatives with a 4-amino group (Type 2 in Figure 1)
instead of a 5-amino group (Type 1 in Figure 1). Almost all
derivatives with a 4-amino group lacked anti-tumor activity,
suggesting that the 5-amino group of TC11 is important for anti-
tumor activity. We next replaced functional groups of the phenyl
ring of TC11 [R1–R4] with others [H, CH3,C 2H5, CH(CH3)2,
C(CH3)3,C F 3, F or Cl]. Substitution of R1 and R4 with a
hydrogen atom (TC1) dramatically decreased the anti-tumor
activity. Furthermore, 5-amino phthalimide derivatives with
methyl groups (TC30), ethyl groups (TC31), fluorine atoms
(TC41) or chlorine (TC42) atoms at the R1 and R4 positions
showed decreased anti-tumor activity. A 5-amino phthalimide
derivative (TC32) with sterically bulky tertiary butyl groups at the
R1 and R3 positions of the phenyl ring showed much the same
anti-tumor activity as TC31 with ethyl groups at the R1 and R4
positions of the phenyl ring. These results indicate that the phenyl
ring requires relatively large functional groups, such as isopropyl
groups, at both R1 and R4. These findings suggested that TC11
with an amino group at the 5-position of phthalimide moiety and
isopropyl groups at both ortho positions of the phenyl ring is the
most potent compound, in terms of growth inhibition of multiple
myeloma cells.
TC11 Induced Apoptosis of MM Cell Lines in vitro and
in vivo
To examine whether TC11-induced apoptosis is dependent on
the caspase pathway, we performed immunoblot analysis of lysates
from TC11-treated KMS34 cells. After treatment with TC11 for
24 h, cleavage of PARP in both cell lines was detected, while
treatment with thalidomide showed no effect (Figure 2A). Like-
wise, cleavage of procaspase-3, 8 and 9 (activated forms of caspase)
was detected following treatment with TC11 (Figure 2B). DNA
fragmentation was also observed in KMS34 cells treated with
TC11 or staurosporine (Figure 2C). Besides these early-phase
events (Fig. 2A–C), we also examined structural change of the cell
membrane during apoptosis in the late phase (Fig. 2D). KMS34
cells were treated with 50 mM TC11 for 96 h. Annexin V-FITC
and propidium iodide (PI) staining, followed by flow cytometric
analyses, showed that TC11 treatment increased both Annexin V-
positive/PI-negative and Annexin V-positive/PI-positive fractions
(early and later apoptotic cells, respectively) of KMS34 cells, while
thalidomide treatment did not. These results suggested that TC11
induced apoptosis depending on activation of caspase-3, 8 and 9.
We next tested the anti-tumor activity of TC11 in vivo. KMS34
tumor xenografts (,50 mm
3) were treated with intraperitoneal
injection of 20 mg/kg TC11 twice with a 3-day interval, followed
by time-course analysis of tumor volume for 15 days (Figure 3A).
After 7 and 14 days, TC11 showed significant tumor suppression
(P,0.05). In the animal experiments, no mouse died and no
macroscopic indications of TC11 toxicity were observed at
autopsy. Hematoxylin-eosin staining of tumor tissue slices showed
that cells with aggregated chromatin were increased in TC11-
treated mice. Cytoplasm of these cells appeared round and little
shrunken (Figure 3B). To examine whether these structural
changes were caused by apoptosis, immunohistochemistry using
anti-ssDNA antibody, which specifically detects fragmented single-
strand DNA, was carried out. As shown in Figure 3C, DNA-
fragmented cells detected by anti-ssDNA antibody were increased
in the tumor tissue treated with TC11 (Figure 3C). These results
Table 1. IC50 values (mM) of thalidomide derivatives for inhibiting proliferation of multiple myeloma cell lines.
Cell line Compound
TC8 TC9 TC10 TC11 TC12 TC13 TC14 TC15 TC16 Thalidomide
KMM1 .50 .50 .50 7 18 5 32 .50 .50 .50
KMM11 .50 .50 .50 6 14 4 7 .50 .50 .50
KMS27 .50 .50 .50 8 25 8 34 .50 .50 .50
KMS34 .50 .50 25 4 16 5 14 .50 .50 .50
RPMI8226 .50 .50 .5 0 7 2 61 12 4.50 .50 .50
doi:10.1371/journal.pone.0038878.t001
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tumor xenograft and exhibited anti-tumor activity in vivo.
Identification of TC11-binding Proteins by mRNA Display
To identify TC11-binding proteins, we used mRNA display
[16], which is a powerful tool for in vitro selection of proteins that
bind to various targets including small-molecular compounds. We
first prepared a cDNA library derived from KMS34 cells, because
our data suggested that KMS34 cells were the most sensitive to
TC11. As a bait, biotinylated TC11 (Figure 4A) was immobilized
on a microfluidic chip and selection of TC11-binding proteins
were performed (Figure 4B). Although the 4-amino group of
TC11, which was experimentally inferred to be critical for the
activity, was biotinylated via a linker, the biotinylation hardly
affect the antitumor activity (data not shown).
Among 11 candidate TC11-binding proteins identified by
mRNA display after 4 rounds of selection, we focused on nucleolar
phosphoprotein nucleophosmin (NPM). Sequencing revealed that
three selected NPM clones, designated 1–183 NPM, encoded the
183 NH2-terminal amino acids of NPM, which contains the
oligomerization domain and a part of the histone binding domain
(Figure 5A). The enrichment efficiency of the NPM clones was
confirmed to be 10
4-fold after 4 rounds of selection by RT-PCR.
NPM is known to be a multifunctional protein involved in both
tumorigenesis and tumor suppression [19], for example, it
regulates cell proliferation and centrosome dupulication [20,21]
and stabilizes oncoprotein Myc [22] and tumor-suppressor protein
p53 [23,24]. Therefore, we hypothesized that NPM is involved in
TC11-induced apoptosis of tumor cells.
To determine whether NPM interacts with TC11 directly, we
examined the interaction between recombinant NPM and TC11.
The initial in vitro binding assay between NPM and TC11
immobilized on beads revealed no interaction (data not shown).
However, as NPM oligomerizes under native conditions [22] and
its oligomerization domain may bind to TC11, we next performed
gel filtration to separate oligomeric and monomeric forms of
Figure 1. IC50 values of TC11 derivatives for inhibiting proliferation of KMS34 cells. KMS34 cells (1610
4 cells/well) in 96-well plate were
incubated with 0–50 mM of indicated compound for 72 h. Then cell viability was determined with WST-1 assay.
doi:10.1371/journal.pone.0038878.g001
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affinity for TC11 (Figure 5B). These results indicate that the
monomeric form of NPM binds to TC11 with a KD value of
6.6610
28 M, while the oligomer binds with a KD value of
1.3610
24 M, so that the monomeric form of NPM is the
interactor with TC11.
TC11 Inhibited Centrosomal Clustering and Thereby
Induced Apoptosis
Although the oligomeric form of NPM regulates tumor-
suppressor protein p53, and inhibition of NPM oligomerization
results in activation of p53 leading to apoptosis of several tumor
cell lines [23,25], we used multiple myeloma cell line KMS34 in
which p53 was inactivated in this study. Moreover, inhibition of
Figure 2. TC11 induces apoptosis of multiple myeloma cells in a caspase-dependent manner. (A) HeLa or KMS34 cells were treated with
0–50 mM TC11 or thalidomide for 24 h. The whole cell lysates were analyzed by Western blotting with anti-PARP antibody. (B) KMS34 cells were
treated with 0, 5 or 25 mM TC11 for 6 h. The whole cell lysates were analyzed by Western blotting with anti-caspase-3, 8 or 9 antibody, respectively.
(C) KMS34 cells were treated with 0–50 mM TC11 or staurosporin A for 6 h. After DNA extraction, 1% agarose gel electrophoresis was performed. (D)
KMS34 cells were treated with 50 mM thalidomide or TC11. After 96 h, cells were stained with FITC-coupled annexin V and propidium iodide, and
induction of apoptosis was evaluated by flow cytometry.
doi:10.1371/journal.pone.0038878.g002
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observed in cell lines with active p53, such as HeLa cells (data not
shown). Therefore, we could rule out the possibility that TC11-
induced apoptosis of tumor cells is p53-pathway-dependent. It has
been reported that NPM is localized on centrosomes during the
mitotic phase of cells and regulates centrosomal duplication
[17,19–21]. Therefore, to examine the effect of TC11 on
centrosomes, we performed immunofluorescence staining and
fluorescence microscopic observation. In order to carefully observe
intra-nuclear structures of TC11-treated cells, and due to difficulty
of gene transfer to multiple myeloma cell lines, we chose HeLa
cells. HeLa cells were incubated with 0–20 mM TC11 for 6 h,
followed by staining with anti-c-tubulin antibody. Many mitotic-
phase cells with multipolar spindles (.2) were observed in the case
of treatment with TC11, while many mitotic cells with bipolar
spindles were observed in the case of treatment with DMSO
(Figure 6A). Quantification of multipolarity indicated that
induction of multipolar mitoses was TC11 concentration-depen-
dent (Figure 6B). Several studies have shown that multipolarity
occurs due to inhibition of centrosomal clustering [26,27]. Thus,
TC11 may inhibit centrosomal clustering and induce multipolar
spindles in mitotic cells.
Additionally, we found that mitosis of cells with multipolar
spindles resulted in multinucleated cells. After 24 h treatment of
Figure 3. TC11 inhibits tumor cell growth and induces apoptosis in vivo. KMS34 (1.2610
7 cells) were injected intraperitoneally into lcr/scid
mice and plasmacytoma was established. When the size of the tumor had reached 50 mm
3 (day 1), 100 mL of TC11 (20 mg/kg) or vehicle alone (10%
DMSO, 1% Tween 80-saline) was injected intraperitoneally into a mouse twice with a 3-day interval (i.e., injections were done on days 1, 2, 4, 5, 7, 8,
10, 11, 13 and 14). (A) The width and length of the plasmacytoma were measured and tumor volume was calculated (n=7). (B) Sections were stained
with hematoxylin and eosin (HE). Cells with aggregated chromatin are indicated by white arrows. (C) Apoptotic cell death was detected by
immunohistochemical staining with anti-single-stranded DNA antibody. Apoptotic cells are indicated by white arrows. The plot on the right side
shows that the difference in the number of ssDNA-positive cells between the vehicle and TC11 groups was statistically significant (Student’s t-test,
P,0.002). For this plot, the number of ss DNA-positive cells was counted in two fields per tumor in five tumors (10 fields in all) in each group.
doi:10.1371/journal.pone.0038878.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38878Figure 4. Schematic representation of in vitro selection of TC11-binding protein using mRNA display. (A) The chemical structure of
biotinylated TC11. (B) A cDNA library derived from KMS34 cells was transcribed, ligated with PEG-Puro spacer (1) and in vitro translated (2) to form a
protein-mRNA conjugates library. The library is injected into micro fluidic chip on which TC11 is immobilized (3) and unbound molecules were
washed away. The bound molecules were eluted and their mRNA portion is amplified by RT-PCR (4). The resulted DNA can be used for the next of
round and analyzed by cloning and sequencing. (See also Materials and Methods.).
doi:10.1371/journal.pone.0038878.g004
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while control cells had a single nucleus (Figure 6C). The former
cells may occur as a result of division of cells with multipolar
spindles. It was recently reported that cells with multiple nuclei
have poor viability and undergo apoptosis [28]. Therefore, we
considered that TC11-induced apoptosis would occur through this
mechanism.
NPM Knockdown Induced Multipolar Spindles and
Apoptosis
To investigate whether NPM is related to the multipolarity of
mitotic cells, we performed a NPM knockdown experiment. HeLa
cells were transfected with siRNA for NPM and after 48 h, NPM
protein levels were confirmed to be repressed to ,20% (Figure 7A).
Figure 5. Monomeric NPM interacts with TC11. (A) The domain structure of NPM and the amino acid sequence predicted by NPM clone 1–183,
which was identified as encoding a binding protein of TC11 by mRNA display using a cDNA library prepared from KMS34 cells. The underlined part
indicates the region (1–183 a. a.) identified by mRNA display selection. The sequence indicated by the solid line corresponds to that encoded by the
ORF of NPM cDNA. (B) Recombinant NPM1–183 was expressed in E. coli and fractionated into monomeric and oligomeric forms. Then, each fraction
was subjected to 10% SDS-PAGE followed by CBB staining (left). A representative biosensorgram of NPM binding on SA sensor chips with
immobilized biotinylated-TC11 is shown. The KD values were determined (right).
doi:10.1371/journal.pone.0038878.g005
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staining with anti-c-tubulin antibody. We found that mitotic cells
with multipolar spindles amounted to 16% of NPM-depleted cells,
but only 2% of control cells (Figure 7B). Additionally, multinu-
cleated cells were observed only among cells transfected with
siRNA for NPM (Figure 7C). To examine whether knockdown of
NPM results in apoptosis, we also performed caspase-9 activity
assay. Caspase-9 activity was 6-fold higher in the case of NPM-
depleted cells than control cells (Figure 7D). We finally examined
whether the inhibitory activity of TC11 on cell proliferation
involves NPM. HeLa cells were treated with TC11 after
knockdown of NPM and the cell viability was determined by
means of WST-1 assay (Figure 7E). We found that TC11 showed
more potent cytotoxicity against NPM-depleted HeLa cells than
against control cells, indicating that down-regulation of NPM
increases the sensitivity of HeLa cells to TC11. These results
suggested that inhibition of NPM function results in multipolarity
of mitotic cells, leading to apoptosis.
Discussion
Although the prognosis of multiple myeloma has been improved
by the introduction of drugs such as thalidomide, lenalidomide
and bortezomib, high-risk patients tend to show a poor response.
We considered that KMS34 cell line would be a good model for
high-risk cases with t(4;14) or del 17. Therefore, we used KMS34
cells to screen for compounds able to induce apoptosis of high-risk
myeloma cells. Among the 29 phthalimide derivatives examined,
TC11 showed significant anti-tumor activity against multiple
myeloma KMS34 cells both in vitro and in vivo, while existing drugs
such as thalidomide and lenalidomide had little or no effect in vitro
(Fig. S2 and unpublished data). These results suggest that TC11
would be effective against multiple myeloma with high-risk
chromosomal changes, t(4;14) and del17 (where the p53 tumor
suppressor gene is located).
We found that TC11 induced apoptosis of tumor cells through
inhibition of centrosomal clustering. Rebacz et al. recently reported
that griseofulvin also inhibits centrosomal clustering [27]. Both
TC11 and griseofulvin induce caspase-3, 8 and 9 activation,
followed by cleavage of PARP. Although their action mechanisms
for inducing apoptosis seem very similar, TC11 is a more potent
inducer of multipolarity and apoptosis. Furthermore, multinucle-
ated cells were observed following treatment with TC11 for 24 h,
probably due to aberrant cell division, because it was previously
reported that multinucleated cells resulted from aberrant cell
division of cells with multipolar spindles [29]. Although the
molecular mechanism that triggers apoptosis after aberrant cell
division is unknown, another study also found that multinucleated
cells show poor survival capability [28]. Thus, inhibition of
centrosomal clustering may play a major role in TC11-induced
apoptosis.
Figure 6. TC11 increases spindle multipolarity, resulting in multinucleation. HeLa cells were treated with 0–20 mM TC11 for 6 h. Then,
immunofluorescence staining of c-tubulin was performed. (A) Representative mitotic cell under the indicated conditions. (B) Mitotic cells with
multipolar spindles were counted under the indicated conditions. At least 100 mitotic cells were counted per sample in three independent
experiments. An asterisk denotes a statistically significant difference according to Student’s t-test (P,0.05). White arrows indicate centrosomes. (C)
HeLa cells were treated with 5 mM TC11 for 24 h, followed by immunofluorescence staining with anti-c-tubulin antibody (green). Nucleus was stained
with DAPI (blue). Bar; 10 mm.
doi:10.1371/journal.pone.0038878.g006
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38878Figure 7. NPM knockdown induces multipolar spindles. HeLa cells were transfected with siRNA for luciferase (control) or NPM. (A) After 48 h,
the whole cell lysates were analyzed by western blotting with antibody against NPM (left) and the band intensities were quantified (right). (B)
Immunofluorescence with anti-NPM (green) and anti-c-tubulin (red) antibody was performed (left). White arrows indicate centrosomes. At least 50
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inducing apoptosis and found that the monomeric form of NPM,
but not oligomeric NPM, bound tightly to TC11. Since the
putative TC11-binding region of NPM includes its oligomerization
domain, and it has been reported that inhibiting oligomerization
of NPM leads to apoptosis [30,31], we hypothesized that TC11
inhibits oligomerization of NPM. However, inhibition of the
oligomerization could not be confirmed with native-PAGE (data
not shown).
Our data suggested that NPM may be involved in the
appearance of multipolar spindles in mitotic cells. NPM is known
to regulate centrosomal duplication during the mitotic phase of
cell division. Although a recent study did not identify NPM as a
protein that was required for centrosomal clustering [32], siRNA-
induced knockdown of the NPM gene has been reported to induce
multipolar spindles in HeLa cells [33], and we also confirmed this
result in the present work. Wang et al. previously reported that
preventing export of NPM to cytoplasm from nucleus through
disruption of the NPM-CRM1 complex with the CRM1 inhibitor
leptomycin B (LMB) resulted in dissociation of NPM from
centrosomes, and thereby led to multipolar spindle formation
[34]. In conflict with that report, our immunofluorescence
experiments indicated that NPM in both TC11 and LMB-treated
cells is localized on centrosomes (Figure S3). In support of our
finding, a recent study by Rousselet indicated that LMB does not
disturb localization of NPM to centrosomes or affect centrosomes
numbers [35]. Therefore, it appears that interaction of TC11 with
NPM may inhibit its centrosomal-regulatory function without
affecting its localization on centrosomes. Little is known about the
region of NPM that is required to regulate centrosomal
duplication or whether NPM exists as oligomer when it localizes
to centrosomes. Moreover, NPM interacts with many kinds of
proteins such as Myc, p53, MDM2 and so on [22–24,36]. It is
possible that other NPM-interacting protein(s) are involved in
centrosomal clustering. Further study is needed to establish the
significance of TC11-NPM interaction for the anticancer effect of
TC11.
We also found that thalidomide did not inhibit centrosomal
clustering (Figure S4). It was previously reported that thalidomide
interferes with tumor angiogenesis. The difference in action
mechanism between thalidomide and TC11 is presumably related
to the difference in their chemical structure. It is noteworthy that
TC11 showed anti-tumor activity against multiple myeloma
KMS34 cells that were resistant to thalidomide (Figure S2) and
lenalidomide (unpublished data).
Inatsuki et al. previously reported that a compound with the
same structure as TC11 inhibited tubulin polymerization [37]. In
our mRNA display experiments, a-tubulin was identified as TC11-
binding protein, as well as NPM (data not shown). Thus, there
may be a possibility that TC11-induced apoptosis is triggered by
inhibition of tubulin polymerization. However, colchicine, which
inhibits tubulin polymerization and induces apoptosis, did not
induce multipolarity of mitotic cells (data not shown) [38].
Moreover, our data showed that repression of NPM leads to
apoptosis and increased sensitivity to TC11. Further experiments,
for example with NPM mutants that do not bind to TC11, might
be helpful to establish the relationship between NPM and TC11-
induced apoptosis. Therefore, if binding of TC11 to a-tubulin
does induce apoptosis by inhibition of tubulin polymerization, we
consider that this occurs independently of the pathway that relates
to inhibition of centrosomal clustering.
In conclusion, we have identified TC11 as a potent suppressor
of proliferation of multiple myeloma cells with high-risk chromo-
somal or genetic changes, both in vitro and in vivo. Our results
suggest that TC11 inhibits the centrosomal-regulatory function of
NPM, thereby inducing multipolar mitotic cells, which undergo
apoptosis. Although further work is required to fully establish the
role of NPM in apoptosis, NPM may become a novel target for
development of antitumor drugs active against myeloma cells.
Materials and Methods
Cell Lines
Multiple myeloma (MM) cell lines (KMM1, KMS11, KMS26,
KMS27, KMS34 and RPMI8226) were established by T Otsuki
(Kawasaki Medical College, Kurashiki, Japan) from Japanese
patients [39] and were maintained in RPMI1640 medium with
10% fetal bovine serum and 1% penicillin/streptomycin. HeLa
cells (RIKEN Cell Bank, 2002) were maintained in DMEM with
10% fetal bovine serum and 1% penicillin/streptomycin. The
identification of cell lines was performed based on an STR
Multiplex method that uses 9 different loci: D5S818, D13S317,
D7S820, D16S539, vWA, TH01, Amelogenin, TPOX and
CSF1PO (Powerplex 1.2 system, Promega Corporation) in 2011.
Compounds
The compounds listed in Figs. S1 and S2 were prepared in 50–
95% yields by refluxing a mixture of phthalic acid anhydride
derivatives and appropriate amines in acetic acid for several hours.
Phthalimide derivatives with an amino group, such as TC1-16 and
TC11-42, were synthesized from phthalic acid anhydride with a
nitro group and appropriate amines, followed by catalytic
hydrogenation under a hydrogen atmosphere. The chemical
structures of synthetic compounds were confirmed by
1H-NMR
spectroscopy and mass spectrometry.
Compound Screening
Synthetic compounds were dissolved in DMSO to make 20 mM
stock solutions. The stock solutions were diluted to 0.5–50 mMi n
medium and distributed into 96-well plates. Then, MM cells
(1610
4 cells/well) were seeded in each well and incubated for
72 h. The number of viable cells was determined with the reagent
WST-1 (Roche, Basel, Switzerland) according to the manufactur-
er’s instructions.
Immunoblot Analysis
Cells were treated with various concentrations of TC11, TC13
or thalidomide for 6–48 h, followed by lysis in RIPA buffer
(50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 0.5%
sodium deoxycholate, 0.05% SDS, 1% NP-40) containing protease
inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). Protein
concentrations were determined using BCA protein assay kit
(Thermo Scientific, Waltham, MA) and 20 mg of protein was
loaded on a 10% or 15% SDS-PAGE gel and analyzed with
mitotic cells were counted in three independent experiments. The ratio of cells with multipolar spindles under the indicated conditions was
quantified (below). (C) Representative multinucleated cell under the indicated conditions. (D) After 72 h, caspase-9 activity was determined using
luminescence-based assay. (E) At 48 h after siRNA transfection, the cells were treated with 0–2.5 mM TC11 and then incubated for a further 72 h. Cell
viability was determined by means of WST-1 assay in three independent experiments. An asterisk denotes a statistically significant difference
according to Student’s t-test (P,0.05). Bar; 10 mm.
doi:10.1371/journal.pone.0038878.g007
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Signaling Technology, Beverly, MA), or NPM (Sigma, St. Louis,
MO, USA). The blots were developed using ECL chemi-
luminescence reagents (GE Healthcare, Waukesha, WI).
DNA Fragmentation Assay
KMS34 cells were treated with various concentrations of TC11
for 6 h. The cells were lysed with lysis buffer (10 mM Tris-HCl
pH 7.4, 10 mM EDTA, 0.2% Triton X-100), followed by
incubation on ice for 15 min. The solution was centrifuged at
10,000g for 20 min and the supernatant was treated with 100 mg/
ml RNase A. The resulting solution was purified with MaXtract
(Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions, followed by isopropanol precipitation. DNA laddering was
detected by EtBr staining after agarose gel electrophoresis.
Flow Cytometric Analysis
KMS26, KMS27 and KMS34 cells (2610
5 cells, respectively)
were incubated with 50 mM thalidomide or TC11 for 96 h. The
cells were stained with an Annexin V-FITC kit (Bender
Medsystems, Vienna, Austria) and Annexin V-positive cells were
quantified with a Becton Dickinson FACSCalibur system (Becton
Dickinson, San Jose, CA).
In vivo Tumor Growth Assay
All of the animal experiments were approved by the Ethics
Committee for Animal Experiments at Keio University School of
Medicine (Approval no. 09118-0). In vivo tumor-inhibitory activity
assay was performed as previously described [40] with several
modifications. Briefly, 3610
7 KMS34 cells were subcutaneously
inoculated into 5-week-old male lcr/scid mice (CLEA, Tokyo,
Japan) and plasmacytoma developed in 4 to 6 weeks. TC11 was
dissolved in DMSO (Sigma) at concentration of 20 mg/mL and
then diluted with 5% carboxymethyl cellulose-saline solution to
2.5 mg/mL. Tumor volume was calculated according to the
following formula: width6length
260.52 [40]. Differences in the
size of tumors on days 7, 10 and 14 were compared and evaluated
by means of Student’s t test. P,0.05 was considered to indicate
statistical significance.
Histopathologic Examination
Histopathologic analysis was performed as previously described
[40] with several modifications. When the subcutaneous tumors
reached 50 mm
3, 5% carboxymethylcellulose or 20 mg/kg TC11
was injected intraperitoneally twice with an interval of 3 days.
After 14 days, the mice were killed and the tumors were isolated.
Tumor samples were fixed with 10% formalin and embedded in
paraffin. Sections were stained with hematoxylin and eosin.
Apoptotic cell death was determined with anti-single-stranded
DNA antibody (DakoCytomation, Carpinteria, CA).
mRNA Display Selection on a Microfluidic Chip
The affinity selection of target proteins of TC11 was performed
by combined mRNA display with a microfluidic system [41]. Total
RNA from KMS34 cells was extracted with an RNeasy mini kit
(Qiagen), followed by purification with a mTRAP mRNA isolation
kit (Active Motif, Carlsbad, CA). Thereafter, preparation of a
cDNA library was performed as previously described [42]. The
resulting cDNA library derived from KMS34 cells was transcribed
using a RiboMAX large-scale RNA production system-SP6
(Promega, Madison, WI). The resulting RNA was purified with
the RNeasy mini kit and ligated with a PEG-puromycin spacer
[p(dCp)2-T(fluorescein)p-PEGp-(dCp)2-puromycin] [16] using T4
RNA ligase (Takara, Otsu, Japan) at 15uC for 15 h. The resulting
RNA-PEG-puromycin library was purified with the RNeasy mini
kit. In vitro translation was performed using wheat germ cell-free
extract (Zoegene). The reaction mixture was subjected to gel
filtration on Sephadex G200 (GE Healthcare) using a 0.864c m
column (Bio-Rad, Richmond, CA) with TBS containing 10 mM
EDTA, and 2-drop fractions were collected. The fluorescence of
mRNA-displayed proteins in eluate fractions was monitored with a
Multi-detection microplate reader Powerscan HT (Dainippon
Pharmaceutical). The biotinylated TC11 was immobilized on SA
sensor chips (GE Healthcare) by passing HBS-EP buffer at a flow
rate of 10 mL/min on a Biacore 3000 instrument (GE Healthcare).
Amounts of biotinylated TC11 immobilized on the chips in flow
cells Fc-1, Fc-2, Fc-3 and Fc-4 were 203, 205, 206 and 207 RU,
respectively. The 4th to 7th fractions containing mRNA-displayed
proteins were diluted with HBS-EP buffer to 300 mL and injected
onto the antigen-immobilized sensor chip. The selection experi-
ments were performed at 25uC with the Biacore 3000 using HBS-
EP buffer at a flow rate of 20 mL/min. After association for 250 s
and dissociation for 1000 s, the sensor surfaces were washed once
with HBS-EP buffer for 600 s. The bound molecules were eluted
competitively from the sensor surface with 7 mL of 200 mM free
TC11 for 600 s. Then, recovered solution was subjected to RT-
PCR in a total volume of 100 mL containing 1 mM dNTPs,
50 mM Tris-HCl, pH 8.0, 75 mM KCl, 3 mM MgCl2,1 0m M
dithiothreitol, 200 U of RNase inhibitor, 500 U of ReverTraAce
(Toyobo), and 50 pmol 3RV30 primer (59-
TTTTTTTTCTTGTCGTCATCGTCCTTGTAG-39), at 50uC
for 30 min and heated at 99uC for 5 min. The RT product was
amplified by PCR with KOD-plus DNA polymerase using primers
Gsp6Omega F (59-GGAAGATCTATTTAGGTGACACTATA-
GAACAACAACAACAACAAACAACAACAAAATG-39) and
3RV30 [24–36 cycles of 30 s at 94uC, 30 s at 58uC, and 2 min
at 68uC]. The resulting DNA was purified using a Wizard PCR
preps DNA purification kit (Promega). Finally, selected DNAs
were cloned using a TOPO TA cloning kit (Invitrogen) and
sequenced with a CEQ 2000 DNA analysis system (Beckman
Coulter, Brea, CA). Genetyx-mac 13.0.10 sequence analysis
software and ClustalX 1.83 were used for alignment and sequence
manipulations.
Surface Plasmon Resonance Analysis
Binding kinetics was determined by surface plasmon resonance
(SPR) analysis with a Biacore 3000 (GE Healthcare). All
experiments were performed at 25uC using HBS-EP buffer.
Biotinylated TC11 was immobilized onto the SA sensor chip (GE
Healthcare). The measurements were performed under conditions
of 276 resonance units of the ligand and at a flow rate of 30 mL/
min. To determine dissociation constants, four different concen-
trations of partially purified monomeric NPM and oligomeric
NPM were injected. The injection period for association was 60 s.
After each measurement, the chip surface was regenerated with
10 mL of Glycine 2.0 (GE Healthcare). The binding data were
analyzed with the steady-state affinity model in the BIAevaluation
software ver. 4.1 (GE Healthcare).
Immunofluorescence Assay and TUNEL Staining
HeLa cells on coverslips were treated with 5–20 mM TC11 for
6 h and then fixed with cold methanol and blocked with 1% BSA
in PBS for 30 min. The sample was stained with antibody against
NPM (Invitrogen) or c-tubulin followed by Alexa488-conjugated
anti-mouse IgG (Invitrogen) or CF568-conjugated anti-rabbit IgG
(Biotium, Hayward, CA), respectively.
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HeLa cells (5610
4 cells) were transfected with NPM siRNA
oligonucleotides (59-ATGGAATGTTATGATAGGACA-39)o r
luciferase siRNA oligonucleotides (59-CGTACGCGGAA-
TACTTCGA-39) (Invitrogen) using a Neon transfection system
(Invitrogen) according to the manufacturer’s instructions.
Measurement of Caspase-9 Activity
Caspase-9 activity was measured with a luminescence-based
assay kit, Caspase-Glo 9 Assay (Promega). After having been
transfected with siRNA, 1610
4 HeLa cells were cultured in 96-
well plates for 72 h. At the end of incubation, 100 ml of assay
reagent was added and incubation was continued for 1 h at room
temperature. Luminescence was measured using a Microplate
luminometer (Promega).
Supporting Information
Figure S1 Chemical structures of phthalimide deriva-
tives.
(TIF)
Figure S2 Screening of compound that inhibit multiple
myeloma cell lines. (A) KMS34 cells (1610
4 cells/well) in 96-
well plate were incubated with 50 mM of each compound from
phthalimide derivatives library for 0, 24, 48 or 72 h. Then cell
viability was determined with WST-1 assay according to
instructions provided by the manufacturer. (B) KMS34 or
RPMI8226 cells were treated with 0, 5 or 50 mM TC11 or
TC15 for 6 h, respectively. The whole cell lysates were analyzed
by Western blot with anti-PARP antibody.
(TIF)
Figure S3 TC11 or LMB does not affect localization of
NPM on centrosome. (A) HeLa cells were treated with 5 mM
TC11 or 100 nM LMB for 6 h. Then, immunofluorescence
staining of NPM (green) or c-tubulin (red) was performed.
Representative mitotic cells under the indicated conditions are
shown. White arrowheads and arrows indicate NPM and
centrosomes, respectively. White arrow indicates centrosome.
Bar; 10 mm.
(TIF)
Figure S4 Thalidomide does not induce multipolarity of
mitotic cells. HeLa cells were treated with 10 or 20 mM
thalidomide for 6 h. Then, immunofluorescence staining of c-
tubulin was performed. At least 50 mitotic cells were counted in
three independent experiments. The ratio of cells with multipolar
spindles under the indicated conditions was quantified.
(TIF)
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